Clinical Trials Sponsored by Ridgeback Biotherapeutics, LP

Total 4 results

Ridgeback Biotherapeutics, LP

Completed

COVID-19 First In Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of EIDD-2801 in Healthy Volunteers

Coronavirus

United Kingdom
Ridgeback Biotherapeutics, LP
Merck Sharp & Dohme LLC

Completed

The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID)

SARS-CoV 2

United States
Ridgeback Biotherapeutics, LP
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19

SARS-CoV-2 Infection, COVID-19

United States
Ridgeback Biotherapeutics, LP
Institut National de Recherche Biomédicale. Kinshasa, République Démocratique...

Available

Open-Label Expanded Access for Ebola-Infected Patients to Receive Human mAb Ansuvimab as Therapeutic or for HR PEP

Hemorrhagic Fever, Ebola

Congo, The Democratic Republic of the, Sierra Leone

3

Subscribe